ReviewACS nano2025
Surface Enhanced Raman Scattering for Biomolecular Sensing in Human Healthcare Monitoring.
Review in ACS nano, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Interpol review of forensic drug chemistry, 2022-2025.Forensic science international. Synergy · 2026Review
- Analysing volatile organic compounds (VOCs) with SERS by bubbling into colloidal nanoparticles.The Analyst · 2026Article
- Plasmonic Nanocrevice-Gap Nanosnowman Particles Enabling Colocalization of Raman Reporters with Super-Localized Electric Fields for Highly Sensitive, Specific, and Quantitative Surface-Enhanced Raman Scattering Biosensing.Journal of the American Chemical Society · 2026Article
- Machine Learning-Assisted SERS Quantification of Sialylated Alpha-Fetoprotein: From Single-Cell Analysis to Hepatocellular Carcinoma Risk Assessment.Small methods · 2026Article
- Gold-Decorated Oxidized Porous Silicon Nanoscaffolds as SERS Platform for Plasmonic Pesticide Sensing.ACS omega · 2026Article
- Coaxially nested component with asymmetric fiber resonant cavity and separation membrane for gaseous and dissolved gases detection.Nature communications · 2026Article
- AI/ML-Assisted SERS Biosensing for Biomolecular Detection: From Direct Spectral Response to Integrated Diagnostic Systems.Biosensors · 2026Review
- Raman Spectroscopy-Based Quantitative Analysis of Fatty Acid Compositions of Lipid Droplets in Live Cells.Analytical chemistry · 2026Article
- Sulfate-Directed Silver Dendrites with Enhanced Stability for Ultrasensitive SERS-Based Therapeutic Drug Monitoring.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Facile Scalable Assembly of Uniform and Layered Plasmonic Hotspots by Force-Assisted Capillary-Mediated Colloidal Transfer.Small (Weinheim an der Bergstrasse, Germany) · 2026Article
- Unlocking the Translational Potential of Nanophotonic Biosensors: Perspectives on Application-Guided Design.ACS photonics · 2025Review
- Early-Stage Pancreatic Cancer Diagnosis: Serum Biomarkers and the Potential for Aptamer-Based Biosensors.Molecules (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Since the 1980s, surface enhanced Raman scattering (SERS) has been used for the rapid and sensitive detection of biomolecules. Whether a label-free or labeled assay is adopted, SERS has demonstrated low limits of detection in a variety of biological matrices. However, SERS analysis has been confined to the laboratory due to several reasons such as reproducibility and scalability, both of which have been discussed at length in the literature. Another possible issue with the lack of widespread adoption of SERS is that its application in point of use (POU) testing is only now being fully explored due to the advent of portable Raman spectrometers. Researchers are now investigating how SERS can be used as the output on several POU platforms such as lateral flow assays, wearable sensors, and in volatile organic compound (VOC) detection for human healthcare monitoring, with favorable results that rival the gold standard approaches. Another obstacle that SERS faces is the interpretation of the wealth of information obtained from the platform. To combat this, machine learning is being explored and has been shown to provide quick and accurate analysis of the generated data, leading to sensitive detection and discrimination of many clinically relevant biomolecules. This review will discuss the advancements of SERS combined with POU testing and the strength that machine learning can bring to the analysis to produce a powerful combined platform for human healthcare monitoring.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.